58 related articles for article (PubMed ID: 17970086)
1. In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer.
Danova M; Bencardino K; Manzoni M; Grasso D; Mariucci S; Rovati B
Anticancer Res; 2007; 27(5A):3399-402. PubMed ID: 17970086
[TBL] [Abstract][Full Text] [Related]
2. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
3. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
[TBL] [Abstract][Full Text] [Related]
4. Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide.
Montella L; Addeo R; Guarrasi R; Cennamo G; Faiola V; Capasso E; Caraglia M; Del Prete S
Eur J Cancer Care (Engl); 2010 Mar; 19(2):200-4. PubMed ID: 19552732
[TBL] [Abstract][Full Text] [Related]
5. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer.
De Rosa L; Lalle M; Perillo A; Pierelli L; Salerno MG; Cortesi E; Martelli O; Pandolfi A; Amodeo R; Marzetti L; Mancuso S; Scambia G
Anticancer Res; 2001; 21(2B):1367-70. PubMed ID: 11396215
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
[TBL] [Abstract][Full Text] [Related]
9. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
Vogel CL; Wojtukiewicz MZ; Carroll RR; Tjulandin SA; Barajas-Figueroa LJ; Wiens BL; Neumann TA; Schwartzberg LS
J Clin Oncol; 2005 Feb; 23(6):1178-84. PubMed ID: 15718314
[TBL] [Abstract][Full Text] [Related]
10. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
[TBL] [Abstract][Full Text] [Related]
11. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
12. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
13. Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.
Bengala C; Pazzagli I; Tibaldi C; Favre C; Vanacore R; Greco F; Mazzoni A; Menconi MC; Macchia P; Conte PF
Cancer; 1998 Mar; 82(5):867-73. PubMed ID: 9486575
[TBL] [Abstract][Full Text] [Related]
14. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
Eckhoff L; Nielsen M; Moeller S; Knoop A
Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
17. Activity of combination chemotherapy, docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer.
Tfayli A; Holter J; Bova A; Venkatappa S; Bullock S; Dooley W; Ozer H
Anticancer Res; 2006; 26(6C):4911-6. PubMed ID: 17214361
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer.
Kaya AO; Coskun U; Buyukberber S; Benekli M; Tekin E; Cifter C; Ozturk B; Yildiz R; Yaman E; Uner A; Yamac D
J BUON; 2010; 15(2):248-54. PubMed ID: 20658717
[TBL] [Abstract][Full Text] [Related]
19. Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
Kümmel S; Thomas A; Paepke S; Schwarz M; Heinrich G; Wetzel A; Elling D; Kohls A; Lichtenegger W; Blohmer JU
Acta Oncol; 2005; 44(3):248-54. PubMed ID: 16076697
[TBL] [Abstract][Full Text] [Related]
20. Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability.
Ballestrero A; Montemurro F; Gonella R; Capaldi A; Danova M; Friedman D; Puglisi M; Aglietta M; Patrone F
Breast Cancer Res Treat; 2003 Dec; 82(3):185-90. PubMed ID: 14703065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
